While CDK12 inactivation results in focal tandem duplications in the genome of prostate cancer cells and generates a large number of neoantigens, which could make patients of this subtype ideal candidates for immunotherapy, further clinical testing is needed to determine the efficacy of this treatment.19 The gene discussed is CDK12; the disease is prostate cancer.